Characteristics | All patients | Tested | Untested | P value | |||
n=250 | n=201 | n=48 | |||||
N | % | N | % | N | % | ||
Age at diagnosis, median (IQR) | 67.0 (59.0–73.0) | 66.0 (59.0–72.0) | 70.0 (61.3–75.0) | 0.023 | |||
Year of diagnosis | 0.497 | ||||||
2016 | 48 | 19.2 | 36 | 17.9 | 12 | 25.0 | |
2017 | 80 | 32.0 | 64 | 31.8 | 15 | 31.3 | |
2018 | 71 | 28.4 | 61 | 30.3 | 10 | 20.8 | |
2019 | 51 | 20.4 | 40 | 19.9 | 11 | 22.9 | |
BMI at diagnosis, kg/m2 | 0.534 | ||||||
<18.5 | 8 | 3.2 | 5 | 2.5 | 3 | 6.3 | |
≥18.5 and ≤24.9 | 108 | 43.2 | 86 | 42.8 | 21 | 43.8 | |
≥25.0 and ≤29.9 | 81 | 32.4 | 65 | 32.3 | 16 | 33.3 | |
≥30 | 46 | 18.4 | 38 | 18.9 | 8 | 16.7 | |
Unknown | 7 | 2.8 | 7 | 3.5 | – | – | |
Country of birth (self-reported) | 0.770 | ||||||
The Netherlands | 192 | 76.8 | 154 | 76.6 | 38 | 79.2 | |
Other | 7 | 2.8 | 6 | 3.0 | – | – | |
Unknown | 51 | 20.4 | 41 | 20.4 | 10 | 20.8 | |
Educational level* (self-reported) | 0.399 | ||||||
Low | 70 | 28.0 | 53 | 26.4 | 16 | 33.3 | |
Medium | 109 | 43.6 | 92 | 45.8 | 17 | 35.4 | |
High | 6 | 2.4 | 4 | 2.0 | 2 | 4.2 | |
Unknown | 65 | 26.0 | 52 | 25.9 | 13 | 27.1 | |
Parity at diagnosis (self-reported) | 0.164 | ||||||
Yes | 157 | 62.8 | 131 | 65.2 | 26 | 54.2 | |
No | 40 | 16.0 | 28 | 13.9 | 12 | 25.0 | |
Unknown | 53 | 21.2 | 42 | 20.9 | 10 | 20.8 | |
Smoking status Former smoker row 70 Tested, 15 Not tested but Total = 86 diagnosis (self-reported) | 0.882 | ||||||
Never smoker | 100 | 40.0 | 79 | 39.3 | 21 | 43.8 | |
Former smoker | 86 | 34.4 | 70 | 34.8 | 15 | 31.3 | |
Current smoker | 21 | 8.4 | 18 | 9.0 | 3 | 6.3 | |
Unknown | 43 | 17.2 | 34 | 16.9 | 9 | 18.8 | |
Family history of cancer at diagnosis (self-reported) | 0.485 | ||||||
Yes | 139 | 55.6 | 115 | 57.2 | 23 | 47.9 | |
No | 67 | 26.8 | 52 | 25.9 | 15 | 31.3 | |
Unknown | 44 | 17.6 | 34 | 16.9 | 10 | 20.8 | |
WHO performance status at diagnosis | 0.217 | ||||||
0 | 142 | 56.8 | 113 | 56.2 | 29 | 60.4 | |
1 | 54 | 21.6 | 43 | 21.4 | 11 | 22.9 | |
2 | 14 | 5.6 | 11 | 5.5 | 3 | 6.3 | |
3 | 3 | 1.2 | 1 | 0.5 | 2 | 4.2 | |
Unknown | 37 | 14.8 | 33 | 16.4 | 3 | 6.3 | |
Frailty at diagnosis (GFI) | 0.533 | ||||||
<4 (non-frail) | 114 | 45.6 | 91 | 45.3 | 23 | 47.9 | |
≥4 (frail) | 47 | 18.8 | 36 | 17.9 | 11 | 22.9 | |
Unknown | 89 | 35.6 | 74 | 36.8 | 14 | 29.2 | |
Histology at diagnosis | <0.001 | ||||||
High-grade serous | 173 | 69.2 | 150 | 74.6 | 22 | 45.8 | |
Non-high-grade serous | 72 | 28.8 | 48 | 23.9 | 24 | 50.0 | |
Adenocarcinoma NOS | 5 | 2.0 | 3 | 1.5 | 2 | 4.2 | |
FIGO stage at diagnosis | 0.018 | ||||||
I/II | 64 | 25.6 | 45 | 22.4 | 19 | 39.6 | |
III/IV | 185 | 74.0 | 155 | 77.1 | 29 | 60.4 | |
Unknown | 1 | 0.4 | 1 | 0.5 | – | – |
One patient who rejected germline test was not included in analysis by testing status.
*Educational levels were defined as follows: low=primary or secondary education or less, medium=vocational education, high=university or higher education.
BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; GFI, Groningen Frailty Index; IQR, Interquartile range; NOS, not otherwise specified.